.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,149,477

« Back to Dashboard

Claims for Patent: 9,149,477

Title:5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
Abstract: Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below: ##STR00001##
Inventor(s): Kesicki; Edward A. (Bothell, WA), Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Bellevue, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Puri; Kamal Deep (Lynnwood, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA)
Assignee: ICOS Corporation (Indianapolis, IN)
Application Number:14/284,331
Patent Claims: 1. A method of inhibiting phosphatidylinositol 3-kinase activity in a cell with a compound ##STR00184## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, further comprising administering the compound or a pharmaceutically acceptable salt thereof to an individual in need thereof.

3. The method of claim 2, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof.

4. The method of claim 2, wherein the compound is ##STR00185##

5. The method of claim 4, wherein the compound is the S-enantiomer.

6. The method of claim 1, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof.

7. The method of claim 1, wherein the compound is ##STR00186##

8. The method of claim 7, wherein the compound is the S-enantiomer.

9. A method of inhibiting phosphatidylinositol 3-kinase delta activity in a cell, comprising administering to an individual in need thereof the compound ##STR00187## or a pharmaceutically acceptable salt thereof.

10. The method of claim 9, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof.

11. The method of claim 9, wherein the compound is ##STR00188##

12. The method of claim 11, wherein the compound is the S-enantiomer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc